24 March 2021 | EirGenix announced that its Ph III clinical trial of EG12014 (proposed trastuzumab biosimilar) has met...
Pearce IP BioBlast®: w/e 26 March 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
When exclusive licensees have no rights to sue or recover damages during patent term extensions
A primer on the questions to be answered by the High Court in the Lundbeck Appeal
In February 2021, H. Lundbeck A/S (Lundbeck) was granted special leave by the High Court to appeal the 2020 Full...
Pearce IP BioBlast®: w/e 19 March 2021
15 March 2021 | Alvotech announced it has completed a second round of its US$100 million private placement. In the...
Federal Court expedites another pharma patent trial
Juno Pharmaceuticals Pty Ltd v Celgene Corporation [2021] FCA 236
Date: 19 March 2021 Court: Federal Court of Australia Judge: Beach J Background Celgene Corporation (Celgene) markets...
Pearce IP BioBlast®: w/e 12 March 2021
04 Mar 21 | US | The US Senate unanimously passed the Ensuring Innovation Act and the Advancing Education on...
True inventor of a patent successfully opposes the patentee’s attempt to surrender it
Michael John Arieni v Sun-Wizard Holding Pty Ltd [2021] APO 20
Date: 11 May 2021 Forum: Australian Patent Office Delegate: Ranganath Subbarayan Background Mr Arieni was a former...
Pearce IP BioBlast®: w/e 05 March 2021
01 Mar 2021 | EU | Biocon and Viatris announced that the CHMP has adopted a positive opinion recommending the marking...
Pearce IP BioBlast®: w/e 26 February 2021
23 Feb 2021 | In its Q4 2020 investor presentation, Fresenius Kabi announced it will launch its biosimilar adalimumab...
Pearce IP BioBlast®: w/e 19 February 2021
13 Feb 2021 | Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution...
Amazon invention a mere business solution and not patentable
Amazon Technologies, Inc. [2021] APO 7
Date: 16 February 2021Forum: Australian Patent OfficeDelegate: Kevin Restrick Background Under Australian law,...
How medicine repurposing could unravel the pharma industry in Australia
TGA seeks consultation on issues relating to the registration of off-label medicines: Part 2
As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper...
Pearce IP BioBlast®: w/e 12 February 2021
04 Feb 2021 | Roche reported a huge erosion of its year on year CER growth in key areas, attributing this decline to...
Exclusive licensees: are you stuck in a “No Standing” zone?
Under Australian law, patent infringement proceedings may be started in the Australian Federal Court only by a...
TGA seeks consultation on issues relating to the registration of off-label use of medicines: Part 1
TGA has invited submissions on its consultation paper released last Thursday designed to facilitate indication...
Pearce IP BioBlast®: w/e 05 February 2021
29 Jan 21 | EU | The CHMP recommended 13 medicines for approval. Among the recommendations were two bevacizumab...
Pearce IP BioBlast®: w/e 29 January 2021
25 Jan 21 | Samsung Bioepis announced the opening of its new headquarters in Incheon. The building was complete in...